

# Thomas Foltynie Mrcp

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7540875/thomas-foltynie-mrcp-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

276  
papers

15,530  
citations

66  
h-index

117  
g-index

295  
ext. papers

19,748  
ext. citations

6.6  
avg, IF

6.64  
L-index

#	Paper	IF	Citations
276	Adaptive deep brain stimulation in advanced Parkinson disease. <i>Annals of Neurology</i> , <b>2013</b> , 74, 449-57	9.4	759
275	The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. <i>Brain</i> , <b>2009</b> , 132, 2958-69	11.2	701
274	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. <i>Lancet Neurology, The</i> , <b>2019</b> , 18, 1091-1102	24.1	562
273	The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. <i>Brain</i> , <b>2004</b> , 127, 550-60	11.2	523
272	The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2013</b> , 84, 1258-64	5.5	416
271	Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2017</b> , 390, 1664-1675	40	352
270	Resting oscillatory cortico-subthalamic connectivity in patients with Parkinson's disease. <i>Brain</i> , <b>2011</b> , 134, 359-74	11.2	304
269	Reducing hemorrhagic complications in functional neurosurgery: a large case series and systematic literature review. <i>Journal of Neurosurgery</i> , <b>2012</b> , 116, 84-94	3.2	278
268	Exenatide and the treatment of patients with Parkinson's disease. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 2730-6	15.9	268
267	Parkinson's disease dementia: a neural networks perspective. <i>Brain</i> , <b>2015</b> , 138, 1454-76	11.2	253
266	Confirmation of functional zones within the human subthalamic nucleus: patterns of connectivity and sub-parcellation using diffusion weighted imaging. <i>NeuroImage</i> , <b>2012</b> , 60, 83-94	7.9	246
265	Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. <i>American Journal of Human Genetics</i> , <b>2016</b> , 98, 500-513	11	225
264	Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. <i>Annals of Neurology</i> , <b>2007</b> , 62, 145-53	9.4	223
263	Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease. <i>Brain</i> , <b>2017</b> , 140, 3191-3203	11.2	209
262	Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. <i>JAMA Neurology</i> , <b>2014</b> , 71, 83-7	17.2	205
261	Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. <i>Brain</i> , <b>2013</b> , 136, 392-9	11.2	201
260	Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. <i>Brain</i> , <b>2014</b> , 137, 1481-95	11.2	201

259	Tourette syndrome deep brain stimulation: a review and updated recommendations. <i>Movement Disorders</i> , <b>2015</b> , 30, 448-71	7	191
258	Bilateral adaptive deep brain stimulation is effective in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 717-21	5.5	183
257	Parkinson's disease, insulin resistance and novel agents of neuroprotection. <i>Brain</i> , <b>2013</b> , 136, 374-84	11.2	180
256	The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action. <i>Drug Discovery Today</i> , <b>2016</b> , 21, 802-18	8.8	168
255	Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD. <i>Annals of Neurology</i> , <b>2005</b> , 57, 564-79.4		160
254	Resting state functional MRI in Parkinson's disease: the impact of deep brain stimulation on 'effective' connectivity. <i>Brain</i> , <b>2014</b> , 137, 1130-44	11.2	157
253	The ongoing pursuit of neuroprotective therapies in Parkinson disease. <i>Nature Reviews Neurology</i> , <b>2015</b> , 11, 25-40	15	154
252	Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. <i>Journal of Parkinsonis Disease</i> , <b>2014</b> , 4, 337-44	5.3	154
251	The natural history of treated Parkinson's disease in an incident, community based cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2011</b> , 82, 1112-8	5.5	153
250	The heterogeneity of idiopathic Parkinson's disease. <i>Journal of Neurology</i> , <b>2002</b> , 249, 138-45	5.5	149
249	Which patients with dystonia benefit from deep brain stimulation? A metaregression of individual patient outcomes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2010</b> , 81, 1383-9	5.5	147
248	Movement-related changes in local and long-range synchronization in Parkinson's disease revealed by simultaneous magnetoencephalography and intracranial recordings. <i>Journal of Neuroscience</i> , <b>2012</b> , 32, 10541-53	6.6	142
247	Stimulating at the right time: phase-specific deep brain stimulation. <i>Brain</i> , <b>2017</b> , 140, 132-145	11.2	138
246	Subthalamic deep brain stimulation sweet spots and hyperdirect cortical connectivity in Parkinson's disease. <i>NeuroImage</i> , <b>2017</b> , 158, 332-345	7.9	131
245	Deep brain stimulation modulates synchrony within spatially and spectrally distinct resting state networks in Parkinson's disease. <i>Brain</i> , <b>2016</b> , 139, 1482-96	11.2	130
244	Adaptive deep brain stimulation for Parkinson's disease demonstrates reduced speech side effects compared to conventional stimulation in the acute setting. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 1388-1389	5.5	130
243	Bilateral globus pallidus stimulation for severe Tourette's syndrome: a double-blind, randomised crossover trial. <i>Lancet Neurology, The</i> , <b>2015</b> , 14, 595-605	24.1	127
242	Efficacy and Safety of Deep Brain Stimulation in Tourette Syndrome: The International Tourette Syndrome Deep Brain Stimulation Public Database and Registry. <i>JAMA Neurology</i> , <b>2018</b> , 75, 353-359	17.2	122

241	Long-term outcome of subthalamic nucleus deep brain stimulation for Parkinson's disease using an MRI-guided and MRI-verified approach. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2014</b> , 85, 1419-25	5.5	120
240	Lysine 27 ubiquitination of the mitochondrial transport protein Miro is dependent on serine 65 of the Parkin ubiquitin ligase. <i>Journal of Biological Chemistry</i> , <b>2014</b> , 289, 14569-82	5.4	120
239	Alpha oscillations in the pedunculopontine nucleus correlate with gait performance in parkinsonism. <i>Brain</i> , <b>2012</b> , 135, 148-60	11.2	120
238	Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. <i>Journal of Neurology</i> , <b>2009</b> , 256, 493-8	5.5	116
237	Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial. <i>JAMA Neurology</i> , <b>2020</b> , 77, 427-434	17.2	113
236	Long-term outcomes of deep brain stimulation in Parkinson disease. <i>Nature Reviews Neurology</i> , <b>2019</b> , 15, 234-242	15	111
235	Subthalamic nucleus phase-amplitude coupling correlates with motor impairment in Parkinson's disease. <i>Clinical Neurophysiology</i> , <b>2016</b> , 127, 2010-9	4.3	109
234	The risk of hardware infection in deep brain stimulation surgery is greater at impulse generator replacement than at the primary procedure. <i>Stereotactic and Functional Neurosurgery</i> , <b>2013</b> , 91, 56-65	1.6	106
233	Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts. <i>Lancet Neurology, The</i> , <b>2017</b> , 16, 620-629	24.1	98
232	Connectivity derived thalamic segmentation in deep brain stimulation for tremor. <i>NeuroImage: Clinical</i> , <b>2018</b> , 18, 130-142	5.3	98
231	Pedunculopontine nucleus deep brain stimulation in Parkinson's disease: A clinical review. <i>Movement Disorders</i> , <b>2018</b> , 33, 10-20	7	98
230	The nucleus basalis of Meynert: a new target for deep brain stimulation in dementia?. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2013</b> , 37, 2676-88	9	98
229	Midline frontal cortex low-frequency activity drives subthalamic nucleus oscillations during conflict. <i>Journal of Neuroscience</i> , <b>2014</b> , 34, 7322-33	6.6	98
228	A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. <i>Human Molecular Genetics</i> , <b>2013</b> , 22, 1039-49	5.6	96
227	Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial. <i>JAMA Neurology</i> , <b>2019</b> , 76, 420-429	17.2	95
226	A Randomized Trial Directly Comparing Ventral Capsule and Anteromedial Subthalamic Nucleus Stimulation in Obsessive-Compulsive Disorder: Clinical and Imaging Evidence for Dissociable Effects. <i>Biological Psychiatry</i> , <b>2019</b> , 85, 726-734	7.9	94
225	Deep brain stimulation for Gilles de la Tourette syndrome: a case series targeting subregions of the globus pallidus internus. <i>Movement Disorders</i> , <b>2011</b> , 26, 1922-30	7	94
224	Estimating the causal influence of body mass index on risk of Parkinson disease: A Mendelian randomisation study. <i>PLoS Medicine</i> , <b>2017</b> , 14, e1002314	11.6	93

223	Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. <i>CNS Drugs</i> , <b>2006</b> , 20, 477-505	6.7	90
222	The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease. <i>Journal of Neurology</i> , <b>2005</b> , 252, 833-8	5.5	90
221	The glucocerebrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease. <i>Movement Disorders</i> , <b>2013</b> , 28, 232-236	7	86
220	Clinical safety of brain magnetic resonance imaging with implanted deep brain stimulation hardware: large case series and review of the literature. <i>World Neurosurgery</i> , <b>2011</b> , 76, 164-72; discussion 69-73	2.1	79
219	A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 341ra76	17.5	77
218	A missense mutation in KCTD17 causes autosomal dominant myoclonus-dystonia. <i>American Journal of Human Genetics</i> , <b>2015</b> , 96, 938-47	11	77
217	Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease. <i>Brain</i> , <b>2015</b> , 138, 3003-15	11.2	74
216	Subthalamic nucleus local field potential activity during the Eriksen flanker task reveals a novel role for theta phase during conflict monitoring. <i>Journal of Neuroscience</i> , <b>2013</b> , 33, 14758-66	6.6	72
215	MRI-guided subthalamic nucleus deep brain stimulation without microelectrode recording: can we dispense with surgery under local anaesthesia?. <i>Stereotactic and Functional Neurosurgery</i> , <b>2011</b> , 89, 318-25	16	70
214	Bilateral Deep Brain Stimulation of the Nucleus Basalis of Meynert for Parkinson Disease Dementia: A Randomized Clinical Trial. <i>JAMA Neurology</i> , <b>2018</b> , 75, 169-178	17.2	69
213	Phase dependent modulation of tremor amplitude in essential tremor through thalamic stimulation. <i>Brain</i> , <b>2013</b> , 136, 3062-75	11.2	68
212	Decision making, impulsivity, and addictions: do Parkinson's disease patients jump to conclusions?. <i>Movement Disorders</i> , <b>2012</b> , 27, 1137-45	7	68
211	Developing and validating Parkinson's disease subtypes and their motor and cognitive progression. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2018</b> , 89, 1279-1287	5.5	66
210	The nature of tremor circuits in parkinsonian and essential tremor. <i>Brain</i> , <b>2014</b> , 137, 3223-34	11.2	65
209	Surgical management of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , <b>2010</b> , 10, 903-14	4.3	65
208	Differentiation and migration of long term expanded human neural progenitors in a partial lesion model of Parkinson's disease. <i>International Journal of Biochemistry and Cell Biology</i> , <b>2004</b> , 36, 702-13	5.6	65
207	Modulation of Beta Bursts in the Subthalamic Nucleus Predicts Motor Performance. <i>Journal of Neuroscience</i> , <b>2018</b> , 38, 8905-8917	6.6	63
206	An approach to deep brain stimulation for severe treatment-refractory Tourette syndrome: the UK perspective. <i>British Journal of Neurosurgery</i> , <b>2011</b> , 25, 38-44	1	61

205	Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data. <i>Lancet Neurology, The</i> , <b>2016</b> , 15, 585-96	24.1	59
204	Predictive factors of speech intelligibility following subthalamic nucleus stimulation in consecutive patients with Parkinson's disease. <i>Movement Disorders</i> , <b>2014</b> , 29, 532-8	7	59
203	Therapeutic subthalamic nucleus deep brain stimulation reverses cortico-thalamic coupling during voluntary movements in Parkinson's disease. <i>PLoS ONE</i> , <b>2012</b> , 7, e50270	3.7	57
202	Features of -associated Parkinson's disease at presentation in the UK study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2018</b> , 89, 702-709	5.5	55
201	Uncovering the underlying mechanisms and whole-brain dynamics of deep brain stimulation for Parkinson's disease. <i>Scientific Reports</i> , <b>2017</b> , 7, 9882	4.9	55
200	Genotype and phenotype in Parkinson's disease: lessons in heterogeneity from deep brain stimulation. <i>Movement Disorders</i> , <b>2013</b> , 28, 1370-5	7	55
199	Management of Advanced Therapies in Parkinson's Disease Patients in Times of Humanitarian Crisis: The COVID-19 Experience. <i>Movement Disorders Clinical Practice</i> , <b>2020</b> , 7, 361-372	2.2	55
198	Understanding DCM: ten simple rules for the clinician. <i>NeuroImage</i> , <b>2013</b> , 83, 542-9	7.9	51
197	Neuroendocrine abnormalities in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2017</b> , 88, 176-185	5.5	50
196	Deep brain stimulation in the treatment of chorea. <i>Movement Disorders</i> , <b>2012</b> , 27, 357-63	7	49
195	Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome. <i>Movement Disorders</i> , <b>2012</b> , 27, 312-5	7	49
194	Image-based analysis and long-term clinical outcomes of deep brain stimulation for Tourette syndrome: a multisite study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2019</b> , 90, 1078-1090	5.5	48
193	Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease: The Effect of Varying Stimulation Parameters. <i>Journal of Parkinson's Disease</i> , <b>2017</b> , 7, 235-245	5.3	48
192	Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease. <i>Neuropharmacology</i> , <b>2018</b> , 136, 260-270	5.5	47
191	Tremor Reduction by Deep Brain Stimulation Is Associated With Gamma Power Suppression in Parkinson's Disease. <i>Neuromodulation</i> , <b>2015</b> , 18, 349-54	3.1	47
190	Human subthalamic nucleus-medial frontal cortex theta phase coherence is involved in conflict and error related cortical monitoring. <i>NeuroImage</i> , <b>2016</b> , 137, 178-187	7.9	46
189	Dopaminergic neuronal imaging in genetic Parkinson's disease: insights into pathogenesis. <i>PLoS ONE</i> , <b>2013</b> , 8, e69190	3.7	46
188	Subthalamic nucleus activity optimizes maximal effort motor responses in Parkinson's disease. <i>Brain</i> , <b>2012</b> , 135, 2766-78	11.2	44

187	Vascular parkinsonism: a review of the precision and frequency of the diagnosis. <i>Neuroepidemiology</i> , <b>2002</b> , 21, 1-7	5.4	44
186	The International Deep Brain Stimulation Registry and Database for Gilles de la Tourette Syndrome: How Does It Work?. <i>Frontiers in Neuroscience</i> , <b>2016</b> , 10, 170	5.1	44
185	Alternating Modulation of Subthalamic Nucleus Beta Oscillations during Stepping. <i>Journal of Neuroscience</i> , <b>2018</b> , 38, 5111-5121	6.6	42
184	Early and marked benefit with GPi DBS for Lubag syndrome presenting with rapidly progressive life-threatening dystonia. <i>Movement Disorders</i> , <b>2009</b> , 24, 1710-2	7	41
183	The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. <i>Movement Disorders</i> , <b>2019</b> , 34, 460-468	7	40
182	Mechanisms Underlying Decision-Making as Revealed by Deep-Brain Stimulation in Patients with Parkinson's Disease. <i>Current Biology</i> , <b>2018</b> , 28, 1169-1178.e6	6.3	40
181	Human subthalamic nucleus in movement error detection and its evaluation during visuomotor adaptation. <i>Journal of Neuroscience</i> , <b>2014</b> , 34, 16744-54	6.6	40
180	Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease. <i>Neurodegenerative Diseases</i> , <b>2014</b> , 13, 24-8	2.3	40
179	Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration. <i>Movement Disorders Clinical Practice</i> , <b>2017</b> , 4, 536-544	2.2	38
178	Distinct mechanisms mediate speed-accuracy adjustments in cortico-subthalamic networks. <i>ELife</i> , <b>2017</b> , 6,	8.9	38
177	Aberrant nigral diffusion in Parkinson's disease: A longitudinal diffusion tensor imaging study. <i>Movement Disorders</i> , <b>2016</b> , 31, 1020-6	7	38
176	Oscillatory Beta Power Correlates With Akinesia-Rigidity in the Parkinsonian Subthalamic Nucleus. <i>Movement Disorders</i> , <b>2017</b> , 32, 174-175	7	38
175	Challenges in detecting disease modification in Parkinson's disease clinical trials. <i>Parkinsonism and Related Disorders</i> , <b>2016</b> , 32, 1-11	3.6	38
174	Minimizing brain shift in stereotactic functional neurosurgery. <i>Operative Neurosurgery</i> , <b>2010</b> , 67, ons213-21; discussion ons221	1.6	37
173	Improving targeting in image-guided frame-based deep brain stimulation. <i>Operative Neurosurgery</i> , <b>2010</b> , 67, 437-47	1.6	37
172	Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes. <i>Brain</i> , <b>2020</b> , 143, 3067-3076	11.2	37
171	Pyramidal tract activation due to subthalamic deep brain stimulation in Parkinson's disease. <i>Movement Disorders</i> , <b>2017</b> , 32, 1174-1182	7	36
170	Analysis of simultaneous MEG and intracranial LFP recordings during Deep Brain Stimulation: a protocol and experimental validation. <i>Journal of Neuroscience Methods</i> , <b>2016</b> , 261, 29-46	3	36

169	Equating scores of the University of Pennsylvania Smell Identification Test and Sniffin' Sticks test in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2016</b> , 33, 96-101	3.6	36
168	Genetic analysis of Mendelian mutations in a large UK population-based Parkinson's disease study. <i>Brain</i> , <b>2019</b> , 142, 2828-2844	11.2	35
167	Dopamine agonists rather than deep brain stimulation cause reflection impulsivity in Parkinson's disease. <i>Journal of Parkinsonis Disease</i> , <b>2013</b> , 3, 139-44	5.3	34
166	Functional imaging of subthalamic nucleus deep brain stimulation in Parkinson's disease. <i>Movement Disorders</i> , <b>2011</b> , 26, 1835-43	7	33
165	The Safety of Using Body-Transmit MRI in Patients with Implanted Deep Brain Stimulation Devices. <i>PLoS ONE</i> , <b>2015</b> , 10, e0129077	3.7	33
164	The Use of Deep Brain Stimulation in Tourette Syndrome. <i>Brain Sciences</i> , <b>2016</b> , 6,	3.4	33
163	Short and long term outcome of bilateral pallidal stimulation in chorea-acanthocytosis. <i>PLoS ONE</i> , <b>2013</b> , 8, e79241	3.7	32
162	Comparison of oscillatory activity in subthalamic nucleus in Parkinson's disease and dystonia. <i>Neurobiology of Disease</i> , <b>2017</b> , 98, 100-107	7.5	31
161	Development and external validation of a prognostic model in newly diagnosed Parkinson disease. <i>Neurology</i> , <b>2016</b> , 86, 986-93	6.5	31
160	Technologies Assessing Limb Bradykinesia in Parkinson's Disease. <i>Journal of Parkinsonis Disease</i> , <b>2017</b> , 7, 65-77	5.3	31
159	Tracking Parkinson's: Study Design and Baseline Patient Data. <i>Journal of Parkinsonis Disease</i> , <b>2015</b> , 5, 947-59	5.3	31
158	Gender distribution of patients with Parkinson's disease treated with subthalamic deep brain stimulation; a review of the 2000-2009 literature. <i>Parkinsonism and Related Disorders</i> , <b>2011</b> , 17, 146-9	3.6	31
157	Urinary incontinence following deep brain stimulation of the pedunculopontine nucleus. <i>Acta Neurochirurgica</i> , <b>2011</b> , 153, 2357-60	3	31
156	GBA-Associated Parkinson's Disease: Progression in a Deep Brain Stimulation Cohort. <i>Journal of Parkinsonis Disease</i> , <b>2017</b> , 7, 635-644	5.3	30
155	C-PE2I and F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study. <i>Movement Disorders</i> , <b>2018</b> , 33, 117-127	7	30
154	Exenatide as a potential treatment for patients with Parkinson's disease: first steps into the clinic. <i>Alzheimeris and Dementia</i> , <b>2014</b> , 10, S38-46	1.2	30
153	The Association Between Type 2 Diabetes Mellitus and Parkinson's Disease. <i>Journal of Parkinsonis Disease</i> , <b>2020</b> , 10, 775-789	5.3	29
152	What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson's Disease: A Post Hoc Analysis. <i>Journal of Parkinsonis Disease</i> , <b>2018</b> , 8, 247-258	5.3	29



151	l-Dopa responsiveness is associated with distinctive connectivity patterns in advanced Parkinson's disease. <i>Movement Disorders</i> , <b>2017</b> , 32, 874-883	7	28
150	Decoding gripping force based on local field potentials recorded from subthalamic nucleus in humans. <i>ELife</i> , <b>2016</b> , 5,	8.9	28
149	Understanding the links between cardiovascular disease and Parkinson's disease. <i>Movement Disorders</i> , <b>2020</b> , 35, 55-74	7	28
148	Subthalamic nucleus local field potential activity helps encode motor effort rather than force in parkinsonism. <i>Journal of Neuroscience</i> , <b>2015</b> , 35, 5941-9	6.6	27
147	Penetrance of Parkinson's Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score. <i>Movement Disorders</i> , <b>2020</b> , 35, 774-780	7	27
146	Parkinson's disease: an update on pathogenesis and treatment. <i>Journal of Neurology</i> , <b>2013</b> , 260, 1433-40;5		27
145	Treatment of dysarthria following subthalamic nucleus deep brain stimulation for Parkinson's disease. <i>Movement Disorders</i> , <b>2011</b> , 26, 2434-6	7	27
144	Subthalamic nucleus gamma activity increases not only during movement but also during movement inhibition. <i>ELife</i> , <b>2017</b> , 6,	8.9	27
143	Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease. <i>Movement Disorders</i> , <b>2021</b> , 36, 424-433	7	27
142	Different effects of dopaminergic medication on perceptual decision-making in Parkinson's disease as a function of task difficulty and speed-accuracy instructions. <i>Neuropsychologia</i> , <b>2015</b> , 75, 577-87	3.2	26
141	Deep brain stimulation for movement disorders: update on recent discoveries and outlook on future developments. <i>Journal of Neurology</i> , <b>2015</b> , 262, 2583-95	5.5	26
140	Subthalamic nucleus deep brain stimulation induces impulsive action when patients with Parkinson's disease act under speed pressure. <i>Experimental Brain Research</i> , <b>2016</b> , 234, 1837-1848	2.3	26
139	Drug Repurposing in Parkinson's Disease. <i>CNS Drugs</i> , <b>2018</b> , 32, 747-761	6.7	25
138	Post hoc analysis of the Exenatide-PD trial-Factors that predict response. <i>European Journal of Neuroscience</i> , <b>2019</b> , 49, 410-421	3.5	25
137	Pallidal stimulation for cervical dystonia does not correct abnormal temporal discrimination. <i>Movement Disorders</i> , <b>2013</b> , 28, 1874-7	7	25
136	Loss of phosphodiesterase 4 in Parkinson disease: Relevance to cognitive deficits. <i>Neurology</i> , <b>2017</b> , 89, 586-593	6.5	24
135	Do we need to revise the tripartite subdivision hypothesis of the human subthalamic nucleus (STN)? Response to Alkemade and Forstmann. <i>NeuroImage</i> , <b>2015</b> , 110, 1-2	7.9	24
134	Is Exenatide a Treatment for Parkinson's Disease?. <i>Journal of Parkinson's Disease</i> , <b>2017</b> , 7, 451-458	5.3	22

133	Structural connectivity predicts clinical outcomes of deep brain stimulation for Tourette syndrome. <i>Brain</i> , <b>2020</b> , 143, 2607-2623	11.2	22
132	Refining the Deep Brain Stimulation Target within the Limbic Globus Pallidus Internus for Tourette Syndrome. <i>Stereotactic and Functional Neurosurgery</i> , <b>2017</b> , 95, 251-258	1.6	21
131	Subthalamic nucleus beta and gamma activity is modulated depending on the level of imagined grip force. <i>Experimental Neurology</i> , <b>2017</b> , 293, 53-61	5.7	20
130	Gene therapy: a viable therapeutic strategy for Parkinson's disease?. <i>Journal of Neurology</i> , <b>2011</b> , 258, 179-88	5.5	20
129	Parkinsonian signs in patients with cervical dystonia treated with pallidal deep brain stimulation. <i>Brain</i> , <b>2018</b> , 141, 3023-3034	11.2	20
128	Changing of the guard: reducing infection when replacing neural pacemakers. <i>Journal of Neurosurgery</i> , <b>2017</b> , 126, 1165-1172	3.2	19
127	Deep brain stimulation has state-dependent effects on motor connectivity in Parkinson's disease. <i>Brain</i> , <b>2019</b> , 142, 2417-2431	11.2	19
126	Motor complications in Parkinson's disease: 13-year follow-up of the CamPaIGN cohort. <i>Movement Disorders</i> , <b>2020</b> , 35, 185-190	7	19
125	Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 1183-1190	5.5	19
124	Dopaminergic treatment modulates sensory attenuation at the onset of the movement in Parkinson's disease: A test of a new framework for bradykinesia. <i>Movement Disorders</i> , <b>2016</b> , 31, 143-6	7	19
123	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. <i>Movement Disorders</i> , <b>2019</b> , 34, 1851-1863	7	18
122	Functional Connectivity of the Pedunculopontine Nucleus and Surrounding Region in Parkinson's Disease. <i>Cerebral Cortex</i> , <b>2017</b> , 27, 54-67	5.1	18
121	The Effect of Short Pulse Width Settings on the Therapeutic Window in Subthalamic Nucleus Deep Brain Stimulation for Parkinson's disease. <i>Journal of Parkinson's Disease</i> , <b>2018</b> , 8, 273-279	5.3	18
120	Successful pallidal deep brain stimulation in 15-year-old with Tourette syndrome: 2-year follow-up. <i>Journal of Neurology</i> , <b>2013</b> , 260, 2417-9	5.5	18
119	Autonomic Dysfunction in Early Parkinson's Disease: Results from the United Kingdom Tracking Parkinson's Study. <i>Movement Disorders Clinical Practice</i> , <b>2017</b> , 4, 509-516	2.2	18
118	Subthalamic nucleus gamma oscillations mediate a switch from automatic to controlled processing: a study of random number generation in Parkinson's disease. <i>NeuroImage</i> , <b>2013</b> , 64, 284-9	7.9	18
117	Variation in Recent Onset Parkinson's Disease: Implications for Prodromal Detection. <i>Journal of Parkinson's Disease</i> , <b>2016</b> , 6, 289-300	5.3	18
116	The Parkinsonian Subthalamic Network: Measures of Power, Linear, and Non-linear Synchronization and their Relationship to L-DOPA Treatment and OFF State Motor Severity. <i>Frontiers in Human Neuroscience</i> , <b>2016</b> , 10, 517	3.3	18

115	Perceptual decision-making in patients with Parkinson's disease. <i>Journal of Psychopharmacology</i> , <b>2014</b> , 28, 1149-54	4.6	17
114	Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets. <i>JAMA Neurology</i> , <b>2021</b> , 78, 464-472	17.2	17
113	Controlling Parkinson's disease with adaptive deep brain stimulation. <i>Journal of Visualized Experiments</i> , <b>2014</b> ,	1.6	16
112	Image-verified deep brain stimulation reduces risk and cost with no apparent impact on efficacy. <i>Movement Disorders</i> , <b>2012</b> , 27, 1585-6; author reply 1586-7	7	16
111	Impact of variants on long-term clinical progression and mortality in incident Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2020</b> , 91, 695-702	5.5	16
110	Bilateral nucleus basalis of Meynert deep brain stimulation for dementia with Lewy bodies: A randomised clinical trial. <i>Brain Stimulation</i> , <b>2020</b> , 13, 1031-1039	5.1	15
109	Noninvasive options for 'wearing-off' in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists. <i>Neurodegenerative Disease Management</i> , <b>2018</b> , 8, 349-360	2.8	15
108	A case of voltage-gated potassium channel antibody-related limbic encephalitis. <i>Nature Clinical Practice Neurology</i> , <b>2006</b> , 2, 339-43; quiz following 343		15
107	Therapeutic Strategies to Treat or Prevent Off Episodes in Adults with Parkinson's Disease. <i>Drugs</i> , <b>2020</b> , 80, 775-796	12.1	14
106	Therapies to Slow, Stop, or Reverse Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , <b>2018</b> , 8, S115-S123	3.3	14
105	Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2019</b> , 90, 768-773	5.5	13
104	Progress towards therapies for disease modification in Parkinson's disease. <i>Lancet Neurology</i> , <b>2021</b> , 20, 559-572	24.1	13
103	Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: Rationale and clinical experience. <i>Progress in Brain Research</i> , <b>2020</b> , 252, 493-523	2.9	12
102	Deep brain stimulation as a treatment for chorea-acanthocytosis. <i>Journal of Neurology</i> , <b>2013</b> , 260, 303-5	5.5	12
101	Apathy and Reduced Speed of Processing Underlie Decline in Verbal Fluency following DBS. <i>Behavioural Neurology</i> , <b>2017</b> , 2017, 7348101	3	12
100	Image-guided and image-verified deep brain stimulation. <i>Movement Disorders</i> , <b>2013</b> , 28, 254	7	12
99	A genome-wide screen for association in Hungarian multiple sclerosis. <i>Journal of Neuroimmunology</i> , <b>2003</b> , 143, 84-7	3.5	12
98	Letter to the Editor: A paradigm shift toward MRI-guided and MRI-verified DBS surgery. <i>Journal of Neurosurgery</i> , <b>2016</b> , 124, 1135-7	3.2	12

97	Effect of Low versus High Frequency Subthalamic Deep Brain Stimulation on Speech Intelligibility and Verbal Fluency in Parkinson's Disease: A Double-Blind Study. <i>Journal of Parkinsonis Disease</i> , <b>2019</b> , 9, 141-151	5.3	12
96	Decisions Made with Less Evidence Involve Higher Levels of Corticosubthalamic Nucleus Theta Band Synchrony. <i>Journal of Cognitive Neuroscience</i> , <b>2016</b> , 28, 811-25	3.1	11
95	Analysis of ATP13A2 in large neurodegeneration with brain iron accumulation (NBIA) and dystonia-parkinsonism cohorts. <i>Neuroscience Letters</i> , <b>2012</b> , 523, 35-8	3.3	11
94	A whole genome association study in multiple sclerosis patients from north Portugal. <i>Journal of Neuroimmunology</i> , <b>2003</b> , 143, 116-9	3.5	11
93	Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease. <i>Movement Disorders</i> , <b>2019</b> , 34, 1505-1515	7	10
92	L-dopa responsiveness in early Parkinson's disease is associated with the rate of motor progression. <i>Parkinsonism and Related Disorders</i> , <b>2019</b> , 65, 55-61	3.6	10
91	Deep brain stimulation of the subthalamic nucleus: histological verification and 9.4-T MRI correlation. <i>Acta Neurochirurgica</i> , <b>2015</b> , 157, 2143-7	3	10
90	Effects of pedunclopontine nucleus stimulation on human bladder function. <i>Neurourology and Urodynamics</i> , <b>2018</b> , 37, 726-734	2.3	10
89	The factor structure of the UPDRS as an index of disease progression in Parkinson's disease. <i>Journal of Parkinsonis Disease</i> , <b>2011</b> , 1, 75-82	5.3	10
88	Short Versus Conventional Pulse-Width Deep Brain Stimulation in Parkinson's Disease: A Randomized Crossover Comparison. <i>Movement Disorders</i> , <b>2020</b> , 35, 101-108	7	10
87	Neural signatures of hyperdirect pathway activity in Parkinson's disease. <i>Nature Communications</i> , <b>2021</b> , 12, 5185	17.4	10
86	Utility of the new Movement Disorder Society clinical diagnostic criteria for Parkinson's disease applied retrospectively in a large cohort study of recent onset cases. <i>Parkinsonism and Related Disorders</i> , <b>2017</b> , 40, 40-46	3.6	9
85	Early nucleus basalis of Meynert degeneration predicts cognitive decline in Parkinson's disease. <i>Brain</i> , <b>2018</b> , 141, 7-10	11.2	9
84	Can Parkinson's disease be cured by stimulating neurogenesis?. <i>Journal of Clinical Investigation</i> , <b>2015</b> , 125, 978-80	15.9	9
83	Video-Based Analyses of Parkinson's Disease Severity: A Brief Review. <i>Journal of Parkinsonis Disease</i> , <b>2021</b> , 11, S83-S93	5.3	9
82	Subcortical evoked activity and motor enhancement in Parkinson's disease. <i>Experimental Neurology</i> , <b>2016</b> , 277, 19-26	5.7	8
81	In a rush to decide: deep brain stimulation and dopamine agonist therapy in Parkinson's disease. <i>Journal of Parkinsonis Disease</i> , <b>2014</b> , 4, 579-83	5.3	8
80	Resting state activity and connectivity of the nucleus basalis of Meynert and globus pallidus in Lewy body dementia and Parkinson's disease dementia. <i>NeuroImage</i> , <b>2020</b> , 221, 117184	7.9	8

79	Bilateral Deep Brain Stimulation of the Globus Pallidus Pars Interna in a Patient with Variant Ataxia-Telangiectasia. <i>Movement Disorders Clinical Practice</i> , <b>2016</b> , 3, 405-408	2.2	8
78	Beta synchrony in the cortico-basal ganglia network during regulation of force control on and off dopamine. <i>Neurobiology of Disease</i> , <b>2019</b> , 127, 253-263	7.5	7
77	Varying time-course of effects of high frequency stimulation of sub-regions of the globus pallidus in patients with parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2015</b> , 21, 597-602	3.6	7
76	Glucagon-like Peptides (GLP-1) Perspectives in Synucleinopathies Treatment. <i>Movement Disorders Clinical Practice</i> , <b>2018</b> , 5, 255-258	2.2	7
75	Standardised Neuropsychological Assessment for the Selection of Patients Undergoing DBS for Parkinson's Disease. <i>Parkinson's Disease</i> , <b>2018</b> , 2018, 4328371	2.6	7
74	A genome wide linkage disequilibrium screen in Parkinson's disease. <i>Journal of Neurology</i> , <b>2005</b> , 252, 597-602	5.5	7
73	Cortical connectivity of the nucleus basalis of Meynert in Parkinson's disease and Lewy body dementias. <i>Brain</i> , <b>2021</b> , 144, 781-788	11.2	7
72	Entraining Stepping Movements of Parkinson's Patients to Alternating Subthalamic Nucleus Deep Brain Stimulation. <i>Journal of Neuroscience</i> , <b>2020</b> , 40, 8964-8972	6.6	6
71	High-frequency peripheral vibration decreases completion time on a number of motor tasks. <i>European Journal of Neuroscience</i> , <b>2018</b> , 48, 1789-1802	3.5	6
70	Glycolysis as a therapeutic target for Parkinson's disease. <i>Lancet Neurology</i> , <b>2019</b> , 18, 1072-1074	24.1	6
69	No evidence for association between an MAOA functional polymorphism and susceptibility to Parkinson's disease. <i>Journal of Neurology</i> , <b>2009</b> , 256, 132-3	5.5	6
68	Skewering the subthalamic nucleus via a parietal approach. <i>Stereotactic and Functional Neurosurgery</i> , <b>2011</b> , 89, 70-5	1.6	6
67	Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson's disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study. <i>BMJ Open</i> , <b>2020</b> , 10, e038911	3	6
66	Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study. <i>BMJ Open</i> , <b>2021</b> , 11, e047993	3	6
65	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. <i>Annals of Neurology</i> , <b>2021</b> , 90, 35-42	9.4	6
64	A Clinically Interpretable Computer-Vision Based Method for Quantifying Gait in Parkinson's Disease. <i>Sensors</i> , <b>2021</b> , 21,	3.8	6
63	Impairment in Theory of Mind in Parkinson's Disease Is Explained by Deficits in Inhibition. <i>Parkinson's Disease</i> , <b>2019</b> , 2019, 5480913	2.6	5
62	Subthalamic nucleus deep brain stimulation for Parkinson's disease: current trends and future directions. <i>Expert Review of Medical Devices</i> , <b>2020</b> , 17, 1063-1074	3.5	5

61	A common polymorphism in is associated with accelerated motor decline in -Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2020</b> , 91, 673-674	5.5	5
60	Comparative epidemiology of incident Parkinson's disease in Cambridgeshire, UK. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 1034-6	5.5	5
59	Pathophysiological heterogeneity in Parkinson's disease: Neurophysiological insights from LRRK2 mutations. <i>Movement Disorders</i> , <b>2017</b> , 32, 1333-1335	7	5
58	Pedunculopontine Nucleus Deep Brain Stimulation for Parkinsonian Disorders: A Case Series. <i>Stereotactic and Functional Neurosurgery</i> , <b>2021</b> , 99, 287-294	1.6	5
57	The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2020</b> , 77, 163-169	3.6	5
56	Successful Treatment of Levodopa/Carbidopa Intestinal Gel Associated "Biphasic-like" Dyskinesia with Pallidal Deep Brain Stimulation. <i>Movement Disorders Clinical Practice</i> , <b>2021</b> , 8, 273-274	2.2	5
55	The BRadykinesia Akinesia INcoordination (BRAIN) Tap Test: Capturing the Sequence Effect. <i>Movement Disorders Clinical Practice</i> , <b>2019</b> , 6, 462-469	2.2	4
54	Chronic Subthalamic Nucleus Stimulation in Parkinson's Disease: Optimal Frequency for Gait Depends on Stimulation Site and Axial Symptoms. <i>Frontiers in Neurology</i> , <b>2019</b> , 10, 29	4.1	4
53	Opicapone Efficacy and Tolerability in Parkinson's Disease Patients Reporting Insufficient Benefit/Failure of Entacapone. <i>Movement Disorders Clinical Practice</i> , <b>2020</b> , 7, 955-960	2.2	4
52	Impact of Subthalamic Deep Brain Stimulation Frequency on Upper Limb Motor Function in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , <b>2018</b> , 8, 267-271	5.3	4
51	Uncertainty, misunderstanding and the pedunculopontine nucleus. <i>Acta Neurochirurgica</i> , <b>2012</b> , 154, 839-841		4
50	Parkinson disease and STN-DBS: cognitive effects in GBA mutation carriers.. <i>Annals of Neurology</i> , <b>2022</b> ,	9.4	4
49	Neural signatures of pathological hyperdirect pathway activity in Parkinson's disease		4
48	Basal Ganglia Pathways Associated With Therapeutic Pallidal Deep Brain Stimulation for Tourette Syndrome. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , <b>2021</b> , 6, 961-972	3.4	4
47	Thalamic-Caudal Zona Incerta Deep Brain Stimulation for Refractory Orthostatic Tremor: A Report of 3 Cases. <i>Movement Disorders Clinical Practice</i> , <b>2017</b> , 4, 105-110	2.2	3
46	Validation of a UPDRS-/MDS-UPDRS-based definition of functional dependency for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2020</b> , 76, 49-53	3.6	3
45	Vocal tics in Tourette's syndrome. <i>Lancet Neurology</i> , <i>The</i> , <b>2016</b> , 15, e1	24.1	3
44	Globus pallidal deep brain stimulation for Tourette syndrome: Effects on cognitive function. <i>Parkinsonism and Related Disorders</i> , <b>2019</b> , 69, 14-18	3.6	3

43	16 A randomised controlled trial of deep brain stimulation in obsessive compulsive disorder: a comparison of ventral capsule/ventral striatum and subthalamic nucleus targets. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2017</b> , 88, A8.2-A9	5.5	3
42	Longitudinal functional connectivity changes related to dopaminergic decline in Parkinson's disease. <i>NeuroImage: Clinical</i> , <b>2020</b> , 28, 102409	5.3	3
41	Novel Programming Features Help Alleviate Subthalamic Nucleus Stimulation-Induced Side Effects. <i>Movement Disorders</i> , <b>2020</b> , 35, 2261-2269	7	3
40	Identification of nonlinear features in cortical and subcortical signals of Parkinson's Disease patients via a novel efficient measure. <i>NeuroImage</i> , <b>2020</b> , 223, 117356	7.9	3
39	Dopaminergic Modulation of Sensory Attenuation in Parkinson's Disease: Is There an Underlying Modulation of Beta Power?. <i>Frontiers in Neurology</i> , <b>2019</b> , 10, 1001	4.1	2
38	Writer's Cramp as the First Symptom of Spinocerebellar Ataxia 14. <i>Movement Disorders Clinical Practice</i> , <b>2015</b> , 2, 41-42	2.2	2
37	Endurance of Short Pulse Width Thalamic Stimulation Efficacy in Intention Tremor. <i>Stereotactic and Functional Neurosurgery</i> , <b>2021</b> , 99, 281-286	1.6	2
36	Computer-vision based method for quantifying rising from chair in Parkinson's disease patients. <i>Intelligence-based Medicine</i> , <b>2021</b> , 6, 100046	2.7	2
35	Author response: Decoding gripping force based on local field potentials recorded from subthalamic nucleus in humans <b>2016</b> ,		2
34	European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part IV: deep brain stimulation. <i>European Child and Adolescent Psychiatry</i> , <b>2021</b> , 1	5.5	2
33	Dynamic Network Connectivity Reveals Markers of Response to Deep Brain Stimulation in Parkinson's Disease. <i>Frontiers in Human Neuroscience</i> , <b>2021</b> , 15, 729677	3.3	2
32	The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability. <i>Drugs and Aging</i> , <b>2021</b> , 38, 355-373	4.7	2
31	Inhibitory Control on a Stop Signal Task in Tourette Syndrome before and after Deep Brain Stimulation of the Internal Segment of the Globus Pallidus. <i>Brain Sciences</i> , <b>2021</b> , 11,	3.4	2
30	Balance between competing spectral states in subthalamic nucleus is linked to motor impairment in Parkinson's disease. <i>Brain</i> , <b>2021</b> ,	11.2	2
29	Development and clinimetric assessment of a nurse-administered screening tool for movement disorders in psychosis. <i>BJPsych Open</i> , <b>2018</b> , 4, 404-410	5	2
28	The Parkinson's Real-World Impact Assessment (PRISM) Study: A European Survey of the Burden of Parkinson's Disease in Patients and their Carers. <i>Journal of Parkinson's Disease</i> , <b>2021</b> , 11, 1309-1323	5.3	2
27	Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome.. <i>Nature Communications</i> , <b>2021</b> , 12, 7342	17.4	2
26	The long-term outcome of impulsive compulsive behaviours in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2019</b> , 90, 1288-1289	5.5	1

25	The effects of deep brain stimulation of the pedunculopontine nucleus on cognition in Parkinson's disease and Progressive Supranuclear Palsy. <i>Clinical Parkinsonism &amp; Related Disorders</i> , <b>2019</b> , 1, 48-51	0.9	1
24	Reply: Deep brain stimulation in Huntington's disease: A 4-year follow-up case report. <i>Movement Disorders</i> , <b>2012</b> , 27, 808-808	7	1
23	How can we judge the 'long term' outcomes of novel interventions in Parkinson's disease?. <i>NeuroReport</i> , <b>2013</b> , 24, 1005-9	1.7	1
22	The future challenges in Parkinson's disease. <i>Journal of Neurology</i> , <b>2004</b> , 251, 361-5	5.5	1
21	The BRadykinesia Akinesia INcoordination (BRAIN) tap test: capturing the sequence effect		1
20	Reply: Pathophysiology of gait disorders induced by bilateral globus pallidus interna stimulation in dystonia. <i>Brain</i> , <b>2020</b> , 143, e4	11.2	1
19	Ropinirole, a dopamine agonist with high D affinity, reduces proactive inhibition: A double-blind, placebo-controlled study in healthy adults. <i>Neuropharmacology</i> , <b>2020</b> , 179, 108278	5.5	1
18	Not only loud but also intelligible. <i>EClinicalMedicine</i> , <b>2020</b> , 24, 100456	11.3	1
17	Non-invasive intervention for motor signs of Parkinson's disease: the effect of vibratory stimuli. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2020</b> ,	5.5	1
16	Stimulation Sweet Spot in Subthalamic Deep Brain Stimulation - Myth or Reality? A Critical Review of Literature. <i>Stereotactic and Functional Neurosurgery</i> , <b>2021</b> , 99, 425-442	1.6	1
15	Long-term success of low-frequency subthalamic nucleus stimulation for Parkinson's disease depends on tremor severity and symptom duration. <i>Brain Communications</i> , <b>2021</b> , 3, fcb165	4.5	1
14	Association of Optic Pathways and Brain Structure With Deep Brain Stimulation of the Nucleus Basalis of Meynert for Parkinson Disease Dementia-Reply. <i>JAMA Neurology</i> , <b>2018</b> , 75, 896-897	17.2	1
13	A Randomized Trial Directly Comparing Ventral Capsule and Anteromedial Subthalamic Nucleus Stimulation in Obsessive-Compulsive Disorder: Clinical and Imaging Evidence for Dissociable Effects. <i>Focus (American Psychiatric Publishing)</i> , <b>2022</b> , 20, 160-169	1.1	0
12	Disease modifying therapies III: Novel targets. <i>Neuropharmacology</i> , <b>2021</b> , 201, 108839	5.5	0
11	A practical guide to troubleshooting pallidal deep brain stimulation issues in patients with dystonia. <i>Parkinsonism and Related Disorders</i> , <b>2021</b> , 87, 142-154	3.6	0
10	PO088 Nigral iron susceptibility in parkinson's disease: a longitudinal study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2017</b> , 88, A34.4-A35	5.5	
9	The surgical anatomy of the pedunculopontine nucleus cannot be disputed, buried or exhumed. <i>Acta Neurochirurgica</i> , <b>2012</b> , 154, 1531-1533	3	
8	TRACKING PARKINSON'S (THE PROBAND STUDY) INTERIM REPORT FROM THE FIRST 1000 CASES. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2013</b> , 84, e2.70-e2	5.5	



- 7      Commentary. *Movement Disorders*, **2013**, 28, 739 7
- 6      Quantifying Stridor Associated with Parkinsonism and Deep Brain Stimulation-A Case Report.. *Movement Disorders Clinical Practice*, **2022**, 9, 91-94 2.2
- 5      Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease: Valuable Programming Insights from Anecdotal Observations. *Stereotactic and Functional Neurosurgery*, **2020**, 98, 62-64 1.6
- 4      Might it Be Possible to Assess Rigidity in PD Patients Remotely?. *Movement Disorders Clinical Practice*, **2021**, 8, 489-490 2.2
- 3      Reply to Comment on: Successful Treatment of Levodopa/Carbidopa Intestinal Gel Associated "Biphasic-Like" Dyskinesia with Pallidal Deep Brain Stimulation. *Movement Disorders Clinical Practice*, **2021**, 8, 814-815 2.2
- 2      Reply to: Subthalamic Nucleus Deep Brain Stimulation as Rescue Therapy for Levodopa Carbidopa Intestinal Gel-Associated Biphasic-Like Dyskinesias. *Movement Disorders Clinical Practice*, **2021**, 8, 1157-1158 2.2
- 1      "Real-Life" Remote Dystonia Assessment: Feasibility, Accuracy, and Practice Implications. *Movement Disorders Clinical Practice*, **2021**, 8, 1269-1271 2.2